Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Compliant Monitoring of Adverse Events

Posted on May 24th, 2017 by in Pharmacovigilance

Developing and maintaining a solid strategy for screening for adverse events is critical for every pharmaceutical company. Without one, an adverse event could be reported in scientific literature without the company knowing — and failure to report it to the regulatory authorities could result in a serious warning. Continue reading “Compliant Monitoring of Adverse Events” »

5 Most popular Pharmacovigilance blog posts of 2016

Posted on January 26th, 2017 by in Pharmacovigilance

The most-read pharmacovigilance posts of the year really demonstrate the breadth and depth of issues that professionals in this area are dealing with. In these blogs, authors tackled subjects as varied as leadership needs, compliance metrics, the role of scientific literature in identifying adverse events Continue reading “5 Most popular Pharmacovigilance blog posts of 2016” »

Quality, Reproducibility, and Integrity in Early Research

Posted on November 30th, 2016 by in Pharma R&D

It is sad to hear about more paper retractions regarding early stage research with the R&D industry (1). Perhaps not surprisingly, the number of scientific publications being retracted for fraud and error has increased in recent years, at a faster rate than the rate of increased publications (2). Continue reading “Quality, Reproducibility, and Integrity in Early Research” »

The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions

Posted on May 6th, 2016 by in Pharmacovigilance

Medical-Literature

After our recent webinar, Elsevier received several questions from attendees. During the next few weeks, we will discuss some of the questions in more detail.  Continue reading “The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions” »